NCT00584493No Longer Available不适用
Treatment Use Study of CP-675,206 for Advanced Melanoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Pfizer
研究概览
简要总结
The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.
详细描述
This is an expanded access trial that canceled prior to enrolling patients.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced melanoma with life expectancy of at least 6 months.
- •Melanoma must be considered unresectable.
- •Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month.
排除标准
- •Patients must not be eligible for participation in any ongoing CP-675,206 clinical studies currently open for enrollment.
- •History of chronic inflammatory or autoimmune disease.
- •History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.
研究者
相似试验
已完成
2 期
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 ExpressionMelanomaNCT00835419Piramal Enterprises Limited12
已完成
1 期
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple MyelomaRelapsed and/or Refractory Multiple MyelomaNCT00882063Piramal Enterprises Limited19
已完成
1 期
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic CancerPancreatic CancerNCT00556023AstraZeneca37
招募中
1 期
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT06238401Hangzhou Adcoris Biopharmacy Co., Ltd77
已完成
2 期
The Safety And Efficacy Of Maintenance Therapy With CP-690,550Crohn's DiseaseNCT01393899Pfizer180